Oral-solid-dose facility opened

Until now, Ergopharm's oral-solid products depended on separate handling of intermediate stages. The new block integrates dispensing, high-shear and fluid-bed granulation, drying, blending, rotary compression and both film and functional coating into a single continuous flow. Each unit operation sits within a qualified HVAC envelope with defined pressure cascades and dust-containment, so that materials move from weighed raw ingredients to coated, inspected tablets without leaving Ergopharm's own quality perimeter.

“Bringing granulation, compression and coating in-house means every oral-solid batch now carries a single, auditable quality history from weighed ingredient to coated tablet.”

Bringing these steps in-house is, above all, a control decision. The facility was commissioned through the standard qualification sequence — Installation, Operational and Performance Qualification (IQ/OQ/PQ) — and its critical processes are being taken through process validation under the Stage 1 design and Stage 2 process-qualification (PPQ) approach, with continued process verification to follow in routine manufacture. Blend uniformity, tablet weight, hardness and coat weight are monitored in line with the intent of ICH Q8(R2) pharmaceutical development and the ICH Q10 pharmaceutical quality system, so that quality is built into the product rather than tested into it at the end.

For distributors, the practical significance is traceability and consistency. Because granulation, compression and coating now share one Batch Manufacturing Record and one Certificate of Analysis chain, each lot carries a cleaner, more auditable history from active ingredient to finished pack. Finished-product testing follows recognised compendial methods — dissolution under USP <711> and uniformity of dosage units under USP <905> — and every batch remains subject to Qualified Person release before dispatch. Illustrative annual capacity for the block is in the order of several hundred million tablets across strengths, though output is set by demand and validated ranges rather than nameplate figures.

For patients and prescribers, the change is intended to be invisible in the best sense: the same prescription-only, serialised, GMP-manufactured tablets, made with fewer external hand-offs and a tighter grip on the variables that govern how a tablet disintegrates and releases. The oral portfolio now sits alongside Ergopharm's sterile injectables on the manufacturing register as a fully in-house line, and stability studies on the new site's batches follow ICH Q1A(R2) climatic-zone conditions to support labelled shelf life for export markets.